Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Randomized, Open-Label, Active-Control Study of REGN9933, a Factor XI Monoclonal Antibody, for Prevention of Venous Thromboembolism After Elective, Unilateral, Total Knee Arthroplasty

Next Previous
Trial Profile

A Phase 2, Multicenter, Randomized, Open-Label, Active-Control Study of REGN9933, a Factor XI Monoclonal Antibody, for Prevention of Venous Thromboembolism After Elective, Unilateral, Total Knee Arthroplasty

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs REGN 9933 (Primary) ; Apixaban; Enoxaparin sodium
  • Indications Venous thromboembolism
  • Focus Therapeutic Use
  • Acronyms ROXI-VTE I
  • Sponsors Regeneron Pharmaceuticals

Most Recent Events

  • 19 Dec 2024 Results presented in a Regeneron Pharmaceuticals Media Release.
  • 04 Jun 2024 Status changed from active, no longer recruiting to completed.
  • 26 Mar 2024 Planned End Date changed from 10 Aug 2024 to 29 May 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top